Published in J Am Geriatr Soc on August 01, 2006
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf (2012) 2.11
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc (2015) 1.51
Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 1.39
Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes (2009) 1.29
Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04
Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. Thromb J (2008) 1.03
Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med (2008) 1.01
Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care (2007) 1.00
Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. J Am Heart Assoc (2013) 0.94
National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother (2013) 0.92
Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? J Gen Intern Med (2009) 0.90
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther (2014) 0.85
[Management and therapy of atrial fibrillation in geriatric patients]. Z Gerontol Geriatr (2012) 0.84
Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review. Mayo Clin Proc (2011) 0.83
Effect of preinjury warfarin use on outcomes after head trauma in Medicare beneficiaries. Am J Surg (2014) 0.80
Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiol Ther (2013) 0.79
Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Curr Med Res Opin (2015) 0.79
Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. Am J Med (2016) 0.78
Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists. Medicine (Baltimore) (2015) 0.78
Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol (2009) 0.77
Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study. J Stroke Cerebrovasc Dis (2013) 0.77
Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. Sci Rep (2016) 0.75
Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol (2016) 0.75
Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75
Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. J Am Geriatr Soc (2016) 0.75
Determining risk factors of bleeding in patients on warfarin treatment. Adv Hematol (2014) 0.75
Factors influencing warfarin response in hospitalized patients. Saudi Pharm J (2015) 0.75
The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation. Cardiovasc Ther (2016) 0.75
Stroke Prevention in Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. Vasc Health Risk Manag (2013) 0.75
Integrating Medication Alert Data into a Clinical Data Repository to Enable Retrospective Study of Drug Interaction Alerts in Clinical Practice. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70
Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med (1999) 4.54
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation (1991) 4.52
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med (1998) 3.91
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med (1996) 3.86
The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med (1996) 3.79
Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med (1989) 3.65
Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med (1998) 3.44
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70
Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology (2000) 2.59
Risks of oral anticoagulant therapy with increasing age. Arch Intern Med (2005) 2.06
National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med (2004) 1.92
Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol (2002) 1.61
Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med (1989) 1.48
Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med (1993) 1.38
Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med (1998) 1.36
Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol (2004) 1.17
Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators. J Am Geriatr Soc (2001) 1.17
Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart (2004) 0.85
People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc (2005) 0.82
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med (2010) 8.28
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 5.89
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
The "gender gap" in authorship of academic medical literature--a 35-year perspective. N Engl J Med (2006) 5.23
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med (2008) 4.83
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Association of prehospital advanced airway management with neurologic outcome and survival in patients with out-of-hospital cardiac arrest. JAMA (2013) 4.14
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation (2006) 3.93
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89
Defining patient complexity from the primary care physician's perspective: a cohort study. Ann Intern Med (2011) 3.83
Improved blood pressure control associated with a large-scale hypertension program. JAMA (2013) 3.80
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med (2002) 3.78
Long-term outcomes of surgical and nonsurgical management of lumbar spinal stenosis: 8 to 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.67
Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. JAMA Intern Med (2013) 3.67
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med (2004) 3.63
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care (2003) 3.57
Video decision support tool for advance care planning in dementia: randomised controlled trial. BMJ (2009) 3.55
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke (2006) 3.49
Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA (2013) 3.30
Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol (2009) 3.28
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Long-term outcomes of surgical and nonsurgical management of sciatica secondary to a lumbar disc herniation: 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.17
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med (2012) 3.16
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke (2003) 3.12
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med (2002) 3.06
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06
Patient-physician connectedness and quality of primary care. Ann Intern Med (2009) 3.01
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA (2002) 2.94
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93
Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med (2005) 2.90
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain (2006) 2.87
Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87
Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res (2008) 2.78
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA (2011) 2.77
Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke (2008) 2.72
Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet (2008) 2.71
Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol (2004) 2.68
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol (2009) 2.59
Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation (2012) 2.56